Novan

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline includes SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novan develops products that tap the anti-bacterial properties of nitric oxide by encapsulating the compound in nano-particles that deliver therapeutic agents to desired body location. They use its proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs. The company is committed to using the power of the human body to create safe and effective treatments. They complement their internal scientific talent with strategic partners around the globe to enable Novan to harness the power of nitric oxide and develop technologies that will help address currently untreated and under-treated medical conditions. It was incorporated in 2008 and is based in Morrisville, North Carolina.

– Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17 th at 1:00 PM ET –

Novan to Participate in the Virtual Investor Roundtable Event

Novan, Inc. (NOVN) CEO David Auld on Q4 Fiscal 2021 Results - Earnings Call Transcript

– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum –

Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results

– Data indicate that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe under the conditions of preclinical study –

Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19

– Company highlights rationale of strategic pathway towards potential commercialization in collaboration with commercial solutions provider, Syneos Health –

Novan Announces Fireside Chat Hosted by Jonathan Aschoff, Ph.D. of ROTH Capital Partners

Company to host conference call and webcast on Wednesday, November 10, 2021, at 8:30 a.m. ET Company to host conference call and webcast on Wednesday, November 10, 2021, at 8:30 a.m. ET

Novan to Report Third Quarter 2021 Financial Results on November 10, 2021

– Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care – – Company received conditional acceptance from U.S. FDA for use of KINSOLUS™ as brand name for SB206, if approved –

Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum

– SB206 demonstrates continued favorable safety profile consistent with previous studies and meets Company's expectations –

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

– Live fireside chat with Paula Brown Stafford, President and Chief Executive Officer of Novan on Tuesday, September 28 at 8:00 AM ET – – Live fireside chat with Paula Brown Stafford, President and Chief Executive Officer of Novan on Tuesday, September 28 at 8:00 AM ET –

Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

– Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum –

Novan Announces Strategic Priorities and Outlines Key Milestones

– Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in patients with molluscum contagiosum –

Novan Engages Syneos Health as Commercial Solutions Provider for SB206

DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a fireside chat during the September 13th – 15th H.C. Wainwright 23rd Annual Global Investment Conference.

Novan to Present at H.C. Wainwright 23rd Annual Global Investment Conference

– Conference call with live audio webcast to be held on Thursday, September 9 th at 8:30 a.m. ET –

Novan to Host Corporate Update Conference Call and Webcast on September 9, 2021

Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q2 2021 Results - Earnings Call Transcript

– Positive data across all three of the Company's priority pipeline development programs, announced in Q2 2021, further validating the potential of its novel, proprietary NITRICIL™ technology –

Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update

KemPharm

Onconova Therapeutics

Cassava Sciences Inc

Investing in biotech stocks isn't for the faint of heart, but these can be some of the most lucrative equities on the market. The post How to Pick the Best Small Cap Biotech Stocks to Buy appeared first on InvestorPlace.

How to Pick the Best Small Cap Biotech Stocks to Buy

Company to host conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET Company to host conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET

Novan to Report Second Quarter 2021 Financial Results on August 12, 2021

– Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less than 0.0001 and no serious adverse events related to treatment with SB206 –

Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum

CHICAGO--(BUSINESS WIRE)--Pritzker Private Capital (“PPC”), a leader in family direct investing, today announced the appointment of Paula Brown Stafford to the Pritzker Advisory Board. Ms. Stafford, currently Chairman and CEO of biotechnology company Novan, brings more than 30 years of healthcare industry experience to the Pritzker Advisory Board and PPC's family of companies. Her appointment will enhance PPC's initiatives to invest in and partner with market-leading healthcare companies, speci

Pritzker Private Capital Appoints Paula Brown Stafford to Pritzker Advisory Board

The stock price of Novan Inc (NASDAQ: NOVN) increased by over 10% during intraday trading. This is why it happened.

Novan Stock Increases Over 10%: Why It Happened

DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that as part of the annual reconstitution of the Russell stock indexes, Novan has been selected to join the Russell Microcap® Index, effective after the U.S. market close on June 25, 2021, according to the list of additions published by FTSE Russell as of June 4, 2021.

Novan Announces Inclusion in Russell Microcap® Index

DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering (the “Offering”) of 3,636,364 shares of common stock at a public offering price of $11.00 per share. All of the shares of common stock sold in the offering were offered by the Company. In addition, the Company granted the underwriter of the Offering a 30-day option to purchase up to an additional 545,454 shares of its common stock. The gross proceeds from the offering were approximately $40 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

Novan Announces Closing of $40 Million Public Offering of Common Stock

Novan Inc (NASDAQ: NOVN) priced its previously announced public offering of 3.6 million shares at $11/share for gross proceeds of approximately $40 million. The offer price represents a 21% discount on the last close price of $13.85 on Wednesday.

Novan Stock Falls After Raising $40M Via Equity At 21% Discount

DURHAM, N.C., June 17, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public offering (the “Offering”) of 3,636,364 shares of common stock at a public offering price of $11.00 per share for gross proceeds of approximately $40 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Novan. All of the shares of common stock to be sold in the offering are being offered by Novan. The Offering is expected to close on or about June 21, 2021, subject to customary closing conditions. In addition, Novan has granted the underwriter of the Offering a 30-day option to purchase up to 545,454 additional shares of its common stock.

Novan Announces Pricing of $40 Million Public Offering of Common Stock

The stock price of Novan, Inc. (Nasdaq: NOVN) fell by over 10% pre-market. This is why it happened.

News for Novan Stock (NOVN)